In previous work, we found that expression of FAK was also enhanced during SCC progression (Agochiya et al., 1999), and that genetic deletion of fak suppressed tumorigenesis, particularly progression to malignant carcinoma in the DMBA/TPA model (McLean et al., 2004). The gene discussed is PTK2; the disease is carcinoma.